NCT03818802

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

Completed NA Last updated 26 February 2025

What this trial tests

NA trial testing Nicotinamide Riboside in Healthy Elderly Volunteers in 53 participants. Completed in 8 November 2024.

Timeline

16 September 2019

Primary endpoint
8 November 2024

8 November 2024

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	53
Start date	16 September 2019
Primary completion	8 November 2024
Estimated completion	8 November 2024
Sites	1 location across United States

Drugs / interventions tested

• Nicotinamide Riboside — full drug profile →
• Placebo

Conditions studied

• Healthy Elderly Volunteers — all drugs for Healthy Elderly Volunteers →

Sponsor

Mayo Clinic

Who can join

Adults 65 to 80, female only, with Healthy Elderly Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Researchers are trying to determine if the vitamin B3 derivative Nicotinamide Riboside (NR) has any effects in bone, skeletal muscle, and metabolic functions and structure in aging.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. NAD<sup>+</sup> metabolism and its roles in cellular processes during ageing.
   Covarrubias AJ, Perrone R, Grozio A, Verdin E. · · 2021 · cited 1089× · PMID 33353981 · DOI 10.1038/s41580-020-00313-x
2. NAD⁺ metabolism: pathophysiologic mechanisms and therapeutic potential.
   Xie N, Zhang L, Gao W, Huang C, et al · · 2020 · cited 744× · PMID 33028824 · DOI 10.1038/s41392-020-00311-7
3. A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks.
   Fang EF, Xie C, Schenkel JA, Wu C, et al · · 2020 · cited 415× · PMID 32971255 · DOI 10.1016/j.arr.2020.101174
4. Epigenetic regulation of aging: implications for interventions of aging and diseases.
   Wang K, Liu H, Hu Q, Wang L, et al · · 2022 · cited 406× · PMID 36336680 · DOI 10.1038/s41392-022-01211-8
5. Clinical Evidence for Targeting NAD Therapeutically.
   Radenkovic D, Reason, Verdin E. · · 2020 · cited 45× · PMID 32942582 · DOI 10.3390/ph13090247
6. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health.
   Alegre GFS, Pastore GM. · · 2023 · cited 44× · PMID 37273100 · DOI 10.1007/s13668-023-00475-y
7. Impact of NAD+ metabolism on ovarian aging.
   Liang J, Huang F, Song Z, Tang R, et al · · 2023 · cited 30× · PMID 38041117 · DOI 10.1186/s12979-023-00398-w
8. The Potential Use of Metabolic Cofactors in Treatment of NAFLD.
   Mardinoglu A, Ural D, Zeybel M, Yuksel HH, et al · · 2019 · cited 29× · PMID 31336926 · DOI 10.3390/nu11071578